EXSCIENTIA LTD announced that it has received $26 million in its series B round of funding on January 7, 2019. The transaction included participation from new investors Celgene Corporation (NasdaqGS:CELG), and GT Healthcare Capital Partners along with existing investor Evotec AG (XTRA:EVT) which invested $6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.4 USD | -0.37% |
|
-5.76% | -15.76% |
10/07 | Exscientia Expands Amazon Web Services Partnership to Support Drug Discovery Platform | MT |
10/07 | Exscientia plc Launches Amazon Web Service AI-Powered Platform to Advance Drug Discovery | CI |
Stocks mentioned in the article
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.76% | 68Cr | |
+24.74% | 4.75TCr | |
-0.47% | 4.2TCr | |
+46.11% | 4.16TCr | |
+25.40% | 3.04TCr | |
+17.96% | 2.76TCr | |
-4.47% | 2.87TCr | |
+50.73% | 1.47TCr | |
+42.56% | 1.35TCr | |
+1.46% | 1.23TCr |
- Stock Market
- Equities
- EXAI Stock
- News Exscientia plc
- EXSCIENTIA LTD announced that it has received $26 million in funding from Evotec AG, Celgene Corporation, GT Healthcare Capital Partners